000179703 001__ 179703
000179703 005__ 20180913061419.0
000179703 02470 $$2ISI$$a000251279800114
000179703 037__ $$aCONF
000179703 245__ $$aTowards new tuberculosis drugs
000179703 269__ $$a2007
000179703 260__ $$c2007
000179703 336__ $$aConference Papers
000179703 520__ $$aThe need for better drugs to treat tuberculosis has never been greater. Despite insufficient funding for discovery research, intensive efforts have been made to find and develop new lead compounds capable of reducing the duration of the present treatment known as DOTS (directly observed therapy short course), from 6 to under 4 months. This minireview describes the progress achieved during the last 5 years and highlights some of the successes without neglecting the problems.
000179703 6531_ $$adirectly observed therapy short course (DOTS)
000179703 6531_ $$amoxifloxacin
000179703 6531_ $$aPa-824
000179703 6531_ $$aR207910
000179703 6531_ $$aserine/threonine kinase
000179703 6531_ $$aSq109
000179703 6531_ $$aMultidrug-Resistant Tuberculosis
000179703 6531_ $$aCombinatorial Lead Optimization
000179703 6531_ $$aMycobacterium-Tuberculosis
000179703 6531_ $$aIn-Vitro
000179703 6531_ $$aNitroimidazopyran Pa-824
000179703 6531_ $$aAntituberculosis Agents
000179703 6531_ $$aBactericidal Activity
000179703 6531_ $$aMurine Tuberculosis
000179703 6531_ $$aAtp Synthase
000179703 6531_ $$aIdentification
000179703 700__ $$0243892$$g177247$$aCole, S. T.
000179703 700__ $$aAlzari, P. M.
000179703 7112_ $$dJul 09-12, 2007$$cGlasgow, SCOTLAND$$aFocus Topic at Life Sciences 2007 Conference
000179703 773__ $$j35$$tBiochemical Society Transactions$$q1321-1324
000179703 909C0 $$xU11742$$0252302$$pUPCOL
000179703 909CO $$pconf$$pSV$$ooai:infoscience.tind.io:179703
000179703 917Z8 $$x164606
000179703 937__ $$aEPFL-CONF-179703
000179703 973__ $$rNON-REVIEWED$$sPUBLISHED$$aEPFL
000179703 980__ $$aCONF